Patients with an early-stage form of lung cancer driven by a rare genetic alteration saw their risk of the disease returning drop by 83 percent when they took a single daily pill after surgery. The drug, selpercatinib, produced a two-year event-free survival rate of 94 percent compared with 70 percent for placebo in the LIBRETTO-432 trial, a randomized study of patients with stage IB to IIIA RET fusion–positive non-small-cell lung cancer. The results carry direct consequences for how surgeons, oncologists, and pathologists handle operable lung tumors, because the size of the benefit could reshape which patients get tested for RET fusions and when.
Why an 83 percent risk reduction changes clinical decisions now
RET fusions account for roughly 1 to 2 percent of non-small-cell lung cancers. That small share has historically meant that many surgical teams do not routinely order RET-specific molecular testing before or after an operation. A treatment effect this large alters that calculus. When a single oral therapy can push two-year event-free survival from 70 percent to 94 percent, the cost of missing a RET fusion diagnosis rises sharply for the patient. Oncologists who treat resectable disease will face growing pressure to add RET testing to the panel of mutations they screen for at diagnosis, not just after a recurrence.
The practical consequence is straightforward: if regulators extend selpercatinib’s label to the post-surgical setting, testing rates for RET fusions in stage IB to IIIA NSCLC are likely to climb faster than testing for other actionable mutations where the adjuvant benefit is smaller or less well established. Surgical referral patterns could shift within two years as community oncologists begin flagging operable patients for molecular profiling earlier in the treatment sequence. That shift would be driven not by guidelines alone but by the sheer magnitude of the event-free survival difference reported in the LIBRETTO-432 data.
LIBRETTO-432 trial results and the FDA record for selpercatinib
The peer-reviewed data behind the headline come from LIBRETTO-432, a phase III, randomized, double-blind, placebo-controlled trial registered under identifier NCT04819100. The study enrolled patients with stage IB to IIIA RET fusion–positive NSCLC who had already undergone complete surgical resection. Investigators assessed the primary endpoint of event-free survival, defined as freedom from disease recurrence, progression, or death. The hazard ratio was 0.17, meaning the risk of any of those events was 83 percent lower in the selpercatinib arm than in the placebo arm. At two years, 94 percent of patients receiving selpercatinib remained event-free, compared with 70 percent of those on placebo.
Selpercatinib, marketed as Retevmo, already holds traditional FDA approval for a different indication. The agency granted that approval for locally advanced or metastatic RET fusion–positive solid tumors, a decision documented in the FDA’s searchable drug database. The existing label covers patients whose cancer has spread or cannot be surgically removed. What the LIBRETTO-432 data now show is that the same drug produces a striking benefit in an earlier disease setting, where the goal of treatment is cure rather than disease control.
The distinction matters because adjuvant therapy, given after surgery to reduce the chance of recurrence, faces a higher evidentiary bar. Regulators typically want to see not just delayed recurrence but also a signal pointing toward longer overall survival. The trial registry on ClinicalTrials.gov confirms the study’s design and eligibility criteria but does not yet include final unblinded outcome data for all secondary endpoints, including overall survival. How regulators interpret the maturing data will determine whether the adjuvant indication moves forward on the strength of event-free survival alone or waits for additional follow-up.
Open questions on safety, survival, and regulatory timing
The published summary of LIBRETTO-432 establishes the event-free survival benefit clearly, but several questions remain before selpercatinib becomes a routine part of post-surgical care. First, the trial’s safety and tolerability profile in the adjuvant population has not been reported in granular, patient-level detail beyond the available publication. Patients taking a daily pill for months or years after surgery face different adherence pressures and side-effect trade-offs than patients with metastatic disease, who are already managing symptoms from cancer itself.
Second, no public statements from FDA reviewers have addressed whether the event-free survival endpoint alone would be sufficient to support an adjuvant approval, or whether the agency will require mature overall survival data. That distinction determines how quickly the drug could reach the market for this use. Adjuvant approvals for targeted therapies in lung cancer, such as those aimed at EGFR mutations, have relied on disease-free or event-free survival as surrogate endpoints, but each case is evaluated individually and in the context of available safety information.
Third, real-world adherence data for selpercatinib in early-stage disease are not yet available. In practice, some patients may stop therapy early because of side effects, cost, or the psychological burden of continuing cancer treatment after a “curative” surgery. Those real-world patterns can narrow the gap between clinical-trial efficacy and everyday effectiveness, especially when treatment is planned for a year or longer.
Post-marketing safety surveillance will also play a prominent role if selpercatinib moves into the adjuvant setting. Clinicians and patients can submit adverse event reports through the FDA’s online MedWatch portal, which feeds into the agency’s broader pharmacovigilance systems. That infrastructure will be important for detecting rare or long-latency side effects that might not surface in a trial population of a few hundred patients.
Implications for testing, workflow, and patient counseling
For hospitals and cancer centers, the LIBRETTO-432 findings raise immediate operational questions. Pathology departments may need to expand multiplex sequencing panels or add reflex testing to ensure that RET fusions are identified on every resected NSCLC specimen where tissue quality allows. Turnaround times will matter: if adjuvant therapy is to begin within a typical six- to 12-week post-operative window, molecular results must be available quickly enough to inform decisions.
Multidisciplinary tumor boards will likely become the venue where RET testing and adjuvant selpercatinib are discussed alongside chemotherapy, immunotherapy, and surveillance alone. Surgeons may need to adjust how they consent patients before surgery, explicitly noting that the operation could be followed by a year or more of targeted therapy depending on molecular findings. Medical oncologists, in turn, will need to balance the promise of an 83 percent relative risk reduction in events against the absolute risk of recurrence for an individual patient, which can vary by stage, comorbidities, and margin status.
For patients, the conversation will be nuanced. On one hand, a two-year event-free survival rate of 94 percent is a compelling figure that many will interpret as a near-assurance of cure. On the other hand, some patients with RET fusion–positive tumors would have remained disease-free without any adjuvant therapy, exposing them to potential side effects without clear personal benefit. Shared decision-making will require transparent discussion of both relative and absolute risk reductions, as well as the uncertainties that remain about long-term outcomes.
What comes next for RET-targeted adjuvant therapy
The LIBRETTO-432 results position selpercatinib as a leading contender to become the standard adjuvant option for early-stage RET fusion–positive NSCLC, but the path from trial to practice is not automatic. Regulatory review, guideline updates, payer coverage decisions, and institutional protocol changes will all shape how quickly the drug is adopted. Comparative data with other systemic approaches, including platinum-based chemotherapy and immunotherapy, will be important for refining treatment algorithms, even if direct head-to-head trials are unlikely.
In the meantime, the message for clinicians is clear: identifying RET fusions in resectable NSCLC can no longer be an afterthought. As more detailed safety and survival data emerge, and as regulators weigh an expanded indication, the combination of precise molecular testing and targeted adjuvant therapy is poised to reshape expectations for a small but clinically significant subset of lung cancer patients.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
